Short Interest in Bone Biologics Co. (NASDAQ:BBLG) Expands By 21.0%

Bone Biologics Co. (NASDAQ:BBLG) saw a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 70,400 shares, a growth of 21.0% from the November 15th total of 58,200 shares. Based on an average daily volume of 3,010,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 13.2% of the shares of the company are short sold.

Bone Biologics Stock Down 1.8 %

BBLG stock opened at $1.12 on Monday. The firm’s 50-day simple moving average is $1.42 and its 200 day simple moving average is $1.50. Bone Biologics has a fifty-two week low of $0.80 and a fifty-two week high of $10.56.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.